Mark Kotter, bit.bio CEO
November 5, 2021 10:42 AM EDTUpdated 11:24 AM
Financing

Cell ther­a­py start­up bit.bio adds $100M+ to its cof­fers and some im­pres­sive names to its board of di­rec­tors

Nicole DeFeudis

Editor

Bit.bio CEO Mark Kot­ter says the last ma­jor rev­o­lu­tion in bio­phar­ma oc­curred around the 1980s, when an­ti­bod­ies — or, as some

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

For­mer Pfiz­er CEO and CFO flip on ac­tivist and say they now sup­port com­pa­ny

‘Just the be­gin­ning’: No­bel Prizes show the AI era has ar­rived in biotech

Ex­clu­sive Q&A: FDA's prin­ci­pal deputy com­mis­sion­er on tak­ing over for Califf, ad­comms, ac­cel­er­at­ed ap­provals and more

AI biotech in­sitro part­ners with Lil­ly on meta­bol­ic dis­ease drugs

CMS looks to $2 out-of-pock­et cap for some com­mon­ly used gener­ic drugs

GSK to pay up to $2.2B to set­tle al­most all Zan­tac-re­lat­ed court cas­es

A service from the Financial Times